-
Mashup Score: 0
In this Q&A, eczema patient, advocate, and “skinfluencer” Alexis Smith offers perspectives on National Eczema Awareness Month and AbbVie’s Under My Skin documentary.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet
-
Mashup Score: 0Editorial Advisory Board Insights for Eczema Awareness Month: Joel Schlessinger, MD - 6 month(s) ago
Joel Schlessinger, MD, shares his atopic dermatitis insights.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet-
💡Expert insights: Dermatology Times Editorial Advisory Board member Joel Schlessinger, MD, shares his insights into the evolving treatment and research landscapes of #AtopicDermatitis this #EczemaAwarenessMonth. https://t.co/SCQW8bte1P
-
-
Mashup Score: 0Home - 6 month(s) ago
This year we’ re leaving our screens behind and meeting in person, because the 22nd Annual Psychopharmacology Update is more than just a conference; we’ re a community. For us, joining together again is an opportunity to enhance the learning experience through valuable face-to-face engagement and interaction. As always, our renowned faculty will bring you the latest advancements in psychiatry, from judicious psychopharmacology, evidence-based combinations, and management of treatment-resistant psychiatric
Source: events.medscapelive.orgCategories: Dermatology, Latest HeadlinesTweet-
2 WEEKS UNTIL: #PsychPharm23 October 27-28 in Cincinnati, Ohio for the 22nd Annual Psychopharmacology Update. 🧪 Learn topics from judicious psychopharmacology, evidence-based combinations, addiction and psychedelics. Click here now: https://t.co/OACsubOFFq #PsychEd https://t.co/oCxFP8CyxN
-
-
Mashup Score: 1Dermatomyositis - 6 month(s) ago
This Patient Page describes the symptoms, diagnosis, and treatment of dermatomyositis.
Source: jamanetwork.comCategories: Dermatology, Latest HeadlinesTweet-
Dermatomyositis (DM) is a condition affecting the skin (dermato) and muscles (myositis). This Patient Page describes the symptoms, diagnosis, and treatment of dermatomyositis. https://t.co/GH8iZk89Km https://t.co/m4UIdt6Jqp
-
-
Mashup Score: 0Treatment-Related Acne After Ruxolitinib Application for Vitiligo Occurred in Patients Without History of Acne - 6 month(s) ago
Overall, acne events were mild or moderate and did not cause patients to discontinue ruxolitinib cream treatment.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet-
An EADV presentation analyzed the characterization and treatment of acne related to patients who applied #ruxolitinib cream for the treatment of #vitiligo in TRuE-V1 and TRuE-V2. https://t.co/z0cJob9Q56
-
-
Mashup Score: 0Diagnosis and Pathophysiology of Vitiligo - 6 month(s) ago
A panel of experts discuss the diagnosis and pathophysiology of vitiligo.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet-
Uncover the latest trends in vitiligo management through expert panel discussions on therapy evaluations, patient outcomes, and care intricacies. Watch here: https://t.co/kk9TY59z6l https://t.co/mdgx7vWGQ8
-
-
Mashup Score: 0Trevi Therapeutics Announces New Phase 2b/3 Results of Haduvio for Prurigo Nodularis - 6 month(s) ago
The continued reduction in WI-NRS was seen in patients who remained in the study through week 52.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet-
Trevi Therapeutics recently announced new results from its phase 2b/3 PRISM open-label extension study evaluating Haduvio for the treatment of #PrurigoNodularis. https://t.co/sabFx4vvwL
-
-
Mashup Score: 0Bimekizumab Achieved Meaningful Clinical Improvements in Hidradenitis Suppurativa, According to Data From EADV - 6 month(s) ago
UCB presented data from the BE HEARD I and BE HEARD II phase 3 studies at this year’s EADV Congress.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet-
UCB recently presented phase 3 data from its BE HEARD I and BE HEARD II phase 3 studies at this year’s EADV Congress, revealing that #bimekizumab achieved high thresholds of meaningful clinical responses in patients with #HidradenitisSuppurativa. https://t.co/PmEUcK0d3z
-
-
Mashup Score: 1
Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.
Source: www.dermatologytimes.comCategories: Dermatology, Latest HeadlinesTweet-
Almirall presented data at the 2023 EADV Congress from its ADvantage and ADvocate studies, both of which supported the presence of clinical improvements of #AtopicDermatitis with #lebrikizumab. https://t.co/5pus83qDbe
-
-
Mashup Score: 0Home - 6 month(s) ago
Recognizing the nuances of pediatric neurofibromatosis type 1 (NF1)-associated tumors and successfully caring for affected patients as part of a multidisciplinary team can be a formidable challenge. In this engaging live session, leaders in the field will challenge participants to identifying clinical hallmarks and collaboratively design individualized care plans for pediatric patients living with NF1-associated tumors. This activity is intended for pediatricians, oncologists, neurologists, surgeons, and
Source: na.eventscloud.comCategories: Dermatology, Latest HeadlinesTweet-
Join experts and learn the latest clinical evidence evaluating pharmacologic therapies for the management of pediatric NF1-associated tumors 📆 October 22, 2023 🏅 1.5 CME Credit 📍 https://t.co/VDcOXD57kr https://t.co/ss5JOTwYqH
-
Eczema patient, advocate, and "skinfluencer" Alexis Smith shares her experiences with eczema and the importance of awareness and representation for those with the condition. #EczemaAwarenessMonth https://t.co/0AbUSx3MMd